ArticleMedical oncology (Northwood, London, England)2013
A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate.JNCI cancer spectrum · 2019Article
- Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I.ESMO open · 2018Article
- New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledDose calculation of adjuvant carboplatin chemotherapy for stage I testicular seminoma, based on area under the concentration curve (AUC), incorporates the glomerular filtration rate (GFR). This retrospective study compares 'gold standard' (51)Cr-ethylenediamine tetraacetic acid ((51)Cr-EDTA) GFR measurements with renal function estimations derived from the Cockcroft-Gault, Jelliffe and Wright formulae. INCLUSION CRITERIA: stage I testicular seminoma treated with a single dose of carboplatin AUC7 at one centre in South Wales, UK, between 2005 and 2011, with contemporaneous (51)Cr-EDTA GFR measurement and serum creatinine. Renal function estimates obtained using Cockcroft-Gault, Jelliffe and Wright formulae were analysed for bias (mean percentage error, MPE) and precision (mean absolute percentage error, MAPE) compared to the gold standard. Sixty-eight patients were identified, median age 40 (range 17-66), median creatinine 82 (range 55-120). For the Cockcroft-Gault, Jelliffe and Wright formulae, respectively, MPE was +12.4, -32.3 and +8.8; MAPE was 16.0, 32.7 and 12.9; and substitution of the calculated GFR result for (51)Cr-EDTA measurement would have resulted in a >10% discrepancy in carboplatin dose in 41.1, 97.1 and 42.6% of patients (predominantly overdoses for the Cockcroft-Gault and Wright formulae, underdoses for the Jelliffe formula). Of the formulae analysed, none accurately correlated with (51)Cr-EDTA GFR measurements.
Indexed as
Identifiers
23864250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.